TOKYO, Jun 26 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) announced today that the issuance details of its 18th tranche of share subscription rights (newly issued share warrants) have been finalized based on the resolution made during the board meeting held on June 10, 2026.
According to the announcement, the exercise price per warrant is set at ¥43,100 (¥43¥1 per share). The calculation method involves averaging the closing prices of ordinary shares traded on the Tokyo Stock Exchange in the month preceding the allocation date, excluding non-trading days. Any fractional amount less than one yen is rounded up.
However, if the calculated average falls below the closing price on the allocation day (or the previous trading day's close if there was no trade on the allocation day), the final price used is the closing price on the allocation day (¥318). Additionally, the total number of warrants issued is 380, with each warrant entitling the holder to purchase 100 ordinary shares of Kringle Pharma, resulting in a total of 38,000 ordinary shares. The recipients of these warrants are seven company employees who will collectively receive 380 warrants.
This issuance aligns with the company’s ongoing strategy to incentivize its workforce through equity-based compensation mechanisms.
🟡 Confidence: Standard AI-translated content.